tbResList Print — HCAs Hydroxycinnamic-acid

Filters: qv=95, qv2=%, rfv=%

Product

HCAs Hydroxycinnamic-acid
Description: <b>Hydroxycinnamic acid</b> compounds (p-coumaric, caffeic acid (CA), ferulic acid) occur most frequently as simple esters with hydroxy carboxylic acids or glucose, while the hydroxybenzoic acid compounds (p-hydroxybenzoic, gallic acid, ellagic acid) are present mainly in the form of glucosides. https://www.sciencedirect.com/topics/chemistry/hydroxycinnamic-acid<br>
Hydroxycinnamic acids (HCAs) are plant-derived phenolic acids (including caffeic, ferulic, p-coumaric, and sinapic acids) with documented antioxidant, anti-inflammatory (NF-κB↓), and context-dependent anticancer effects in cellular and preclinical models. Mechanistic themes include activation of the Nrf2/ARE antioxidant response, suppression of pro-inflammatory and survival pathways (such as NF-κB and PI3K/AKT), modulation of MAPK signaling, and downstream effects on cell-cycle, apoptosis, invasion, and angiogenesis. Oral exposure is influenced by rapid metabolism (phase II conjugates) and food matrix effects, which affects systemic bioavailability and translational relevance. Biological effects vary by specific hydroxycinnamic derivative and its conjugated/esterified form. (Caffeic acid ≠ ferulic acid ≠ sinapic acid)<br>
<br>
-Ferulic acid and p‐coumaric acid are naturally occurring hydroxycinnamic acids found in many plant-based foods (such as whole grains, fruits, and vegetables)<br>
<br>
CA showed pro-oxidant potential due to its ability to interact with metals like copper, inducing lipid peroxidation and causing DNA damage within tumor cells through either oxidation or covalent adduct formation.<br>
<br>
Summary:<br>
-HCAs are classically antioxidant<br>
-Such as caffeic acid, ferulic acid, and sinapic acid (SA)<br>
-May increase sensitivity to
<a href="https://nestronics.ca/dbx/tbResList.php?qv=95&tsv=1106&wNotes=0">chemotherapy</a><br>
-Bioavailability is problem. Formulation strategies (e.g., liposomal or encapsulated forms) are investigated to improve systemic exposure.<br>
-Propolis has caffeic acid (Caffeic acid (0.639–4.172 mg/g propolis)<br>
-SA at higher concentrations may acts as a potent pro-oxidant agent<br>
-SA may act in collaboration with other chemotherapeutic agents to improve treatment sensitivity.
-Co-administration of caffeic acid or CAPE with other anti-tumor compounds (e.g., gallic acid) has shown additive or synergistic effects in selected models<br>
-Combination of caffeic acid and endogenous copper ions can result in oxidative damage<br>
-Ferulic Acid (abundant in whole grains,popcorn): upregulate apoptotic protein and downregulate anti-apoptotic protein.upregulating (BAX), (p53), (CYCS) and downregulating (Bcl-2),<br>
<br>


<!-- Hydroxycinnamic Acid (HCA) — Time-Scale Flagged Pathway Table -->
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>

<tr>
<td>1</td>
<td>Nrf2/ARE antioxidant response (Keap1-Nrf2-HO-1)</td>
<td>Stress adaptation modulation (context-dependent)</td>
<td>Nrf2 ↑; HO-1 & GSH systems ↑</td>
<td>R, G</td>
<td>Endogenous antioxidant upshift</td>
<td>Hydroxycinnamic acids commonly promote Nrf2 nuclear translocation and elevate antioxidant defense enzymes; this is one of the most consistent in vivo correlates.</td>
</tr>

<tr>
<td>2</td>
<td>NF-κB inflammatory transcription</td>
<td>NF-κB ↓; pro-inflammatory cytokine programs ↓ (reported)</td>
<td>Inflammation tone ↓; protective in injury models</td>
<td>R, G</td>
<td>Anti-inflammatory signaling</td>
<td>Hydroxycinnamic acids are widely reported to reduce NF-κB activity and downstream cytokine expression across inflammation and tumor models.</td>
</tr>

<tr>
<td>3</td>
<td>ROS / oxidative stress modulation</td>
<td>Oxidative stress ↓ (often); ROS direction variable</td>
<td>Oxidative injury ↓ in stress models</td>
<td>P, R, G</td>
<td>Redox buffering (context-dependent)</td>
<td>These acids are generally antioxidant, but in certain cancer models or at higher concentrations they may affect redox dynamics differentially.</td>
</tr>

<tr>
<td>4</td>
<td>Cell-cycle checkpoints (Cyclin D1/CDK4/6; checkpoints)</td>
<td>Cell-cycle arrest ↑ (reported); Cyclin/CDKs ↓</td>
<td>↔</td>
<td>G</td>
<td>Cytostasis</td>
<td>Largely late phenotype outcome linked to signaling changes.</td>
</tr>

<tr>
<td>5</td>
<td>Apoptosis (intrinsic/mitochondrial & caspase-linked)</td>
<td>Apoptosis ↑; caspase activation ↑ (reported)</td>
<td>↔ (less activation in normal contexts)</td>
<td>G</td>
<td>Cell death execution</td>
<td>Dependent on model and oxidative stress context; not as “direct” as classical mitochondrial toxins.</td>
</tr>

<tr>
<td>6</td>
<td>MAPK re-wiring (ERK / JNK / p38)</td>
<td>MAPK modulation (context-dependent)</td>
<td>↔</td>
<td>P, R, G</td>
<td>Signal reprogramming</td>
<td>Directions vary by tissue, stress levels, and derivative; avoid fixed arrows for all MAPKs unless model-specific evidence is provided.</td>
</tr>

<tr>
<td>7</td>
<td>PI3K → AKT (± mTOR) survival axis</td>
<td>PI3K/AKT modulation (reported)</td>
<td>↔</td>
<td>R, G</td>
<td>Survival/growth modulation</td>
<td>Often reported as downstream of NF-κB suppression and redox buffering.</td>
</tr>

<tr>
<td>8</td>
<td>Invasion / metastasis programs (MMPs / EMT)</td>
<td>MMPs ↓; migration-invasion ↓ (reported)</td>
<td>↔</td>
<td>G</td>
<td>Anti-invasive phenotype</td>
<td>Observed as downstream phenotypes; direction depends on specific hydroxycinnamic acid derivative.</td>
</tr>

<tr>
<td>9</td>
<td>Angiogenesis signaling (VEGF & angiogenic outputs)</td>
<td>VEGF ↓; angiogenesis markers ↓ (reported)</td>
<td>↔</td>
<td>G</td>
<td>Anti-angiogenic support</td>
<td>Later phenotype marker; linked to reduced pro-inflammatory and survival signaling.</td>
</tr>

<tr>
<td>10</td>
<td>Bioavailability / metabolism constraint (conjugation; food matrix dependence)</td>
<td>Systemic exposure variable; rapid conjugation</td>
<td>—</td>
<td>—</td>
<td>Translation constraint</td>
<td>Hydroxycinnamic acids are absorbed but rapidly metabolized (phase II conjugates); food matrix alters bioaccessibility and systemic exposure.</td>
</tr>
</table>

<p><b>Time-Scale Flag (TSF):</b> P / R / G</p>
<ul>
<li><b>P</b>: 0–30 min (primary/rapid effects; early redox interactions)</li>
<li><b>R</b>: 30 min–3 hr (acute stress-response + transcription signaling shifts)</li>
<li><b>G</b>: &gt;3 hr (gene-regulatory adaptation and phenotype-level outcomes)</li>
</ul>

Pathway results for Effect on Cancer / Diseased Cells

Redox & Oxidative Stress

antiOx↑, 1,   Catalase↑, 1,   GPx↑, 1,   GSH↑, 1,   lipid-P↓, 1,   NRF2↑, 1,   ROS↑, 4,   ROS⇅, 2,   SOD↑, 1,  

Mitochondria & Bioenergetics

MMP↓, 1,  

Core Metabolism/Glycolysis

Glycolysis↓, 1,   PKM2↓, 1,   p‑PKM2↓, 1,  

Cell Death

p‑Akt↓, 1,   BAX↑, 1,   Bax:Bcl2↑, 1,   Casp3↑, 2,   cl‑Casp3↑, 1,   Casp8↑, 1,   Casp9↑, 1,   Cyt‑c↑, 1,   MAPK↓, 1,   p27↑, 1,   TRAILR↑, 1,  

Transcription & Epigenetics

tumCV↓, 2,  

Autophagy & Lysosomes

TumAuto↑, 1,  

DNA Damage & Repair

DNAdam↑, 1,   P53↑, 1,   cl‑PARP↑, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence

CDK1↑, 1,   Cyc↓, 1,   P21↑, 1,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State

EMT↓, 1,   GSK‐3β↓, 1,   TumCG↓, 2,  

Migration

E-cadherin↑, 1,   MMP2↓, 2,   MMP9↓, 2,   Snail↓, 1,   TGF-β↓, 1,   TumCI↓, 1,   TumCP↓, 1,   TumMeta↓, 1,   Vim↓, 1,  

Angiogenesis & Vasculature

angioG↓, 2,   VEGF↓, 2,  

Immune & Inflammatory Signaling

COX2↓, 2,   Igs↓, 1,   Igs↑, 1,   Inflam↓, 1,   NF-kB↓, 3,  

Drug Metabolism & Resistance

ChemoSen↑, 2,   Dose↓, 1,   Dose∅, 4,   Dose?, 1,   eff↑, 1,   RadioS↑, 1,   selectivity↑, 2,  

Functional Outcomes

AntiCan↑, 1,   ChemoSideEff↓, 1,  
Total Targets: 62

Pathway results for Effect on Normal Cells

Redox & Oxidative Stress

antiOx↑, 1,  

Drug Metabolism & Resistance

BioAv↓, 2,  

Functional Outcomes

toxicity↓, 1,  
Total Targets: 3

Research papers

Year Title Authors PMID Link Flag
2024Copper-assisted anticancer activity of hydroxycinnamic acid terpyridine conjugates on triple-negative breast cancerAnindya Roy39479915https://pubmed.ncbi.nlm.nih.gov/39479915/0
2019Green synthesis of copper oxide nanoparticles using sinapic acid: an underpinning step towards antiangiogenic therapy for breast cancer312301300
2024Anticancer potential of hydroxycinnamic acids: mechanisms, bioavailability, and therapeutic applicationsFatma Duygu Ceylanhttps://link.springer.com/article/10.1007/s00210-024-03396-x0
2023Anticancer Activity of Sinapic Acid by Inducing Apoptosis in HT-29 Human Colon Cancer Cell Line 2023Şeyma Taştemurhttps://utoronto.scholaris.ca/server/api/core/bitstreams/3fb6eeed-c71d-40e9-912b-6d1d1ecf5fa7/content0
2022Mechanisms involved in the anticancer effects of sinapic acidAnandakumar Pandihttps://bnrc.springeropen.com/articles/10.1186/s42269-022-00943-50
2022The Mixture of Ferulic Acid and P-Coumaric Acid Suppresses Colorectal Cancer through lncRNA 495810/PKM2 Mediated Aerobic GlycolysisKaili CuiPMC9603647https://pmc.ncbi.nlm.nih.gov/articles/PMC9603647/0
2021Lung cancer induced by Benzo(A)Pyrene: ChemoProtective effect of sinapic acid in swiss albino miceXinglong HuPMC8626324https://pmc.ncbi.nlm.nih.gov/articles/PMC8626324/0
2018Chapter 8 - Hydroxycinnamic Acids: Natural Sources, Biosynthesis, Possible Biological Activities, and Roles in Islamic MedicineHesham R. El-Seedihttps://www.sciencedirect.com/science/article/abs/pii/B97804446406800000850
20182'-hydroxycinnamaldehyde inhibits cancer cell proliferation and tumor growth by targeting the pyruvate kinase M2Yae Jin Yoon30009856https://pubmed.ncbi.nlm.nih.gov/30009856/0
2012Artepillin C (3,5-diprenyl-4-hydroxycinnamic acid) sensitizes LNCaP prostate cancer cells to TRAIL-induced apoptosisEWELINA SZLISZKAPMC3582787https://pmc.ncbi.nlm.nih.gov/articles/PMC3582787/0
2012Anticancer Properties of Hydroxycinnamic Acids -A ReviewLuana Rocha0
2007Prooxidant activity of hydroxycinnamic acids on DNA damage in the presence of Cu(II) ions: mechanism and structure-activity relationshipLi-Fang Zheng17764801https://pubmed.ncbi.nlm.nih.gov/17764801/0